In his role as investor, Matthew McConaughey backs Texas startup

alright, alright, alright

Matthew McConaughey invests in startups, including one based in Austin. University of Texas at Austin/Facebook

Matthew McConaughey is far more than an Oscar-winning actor. He’s the “Minister of Culture” for the University of Texas. He’s a professor at UT and a best-selling author. And he’s co-owner of Austin FC, the Major League Soccer team.

But did you know the Austin celebrity also invests in startups?

McConaughey owns a stake in several businesses, and it turns out one of them is based in Austin. In an email interview with Fast Company magazine, McConaughey revealed he’s an investor in Workrise, an Austin company whose workforce management platform matches skilled workers with employers in the energy industry.

As an investor, McConaughey says he looks for companies “that have a purpose to uplift, empower, construct, redefine, and bring a new or renewed health to individuals, communities, and systems.”

Formerly known as RigUp, Workrise rebranded in early 2021. Since its founding eight years ago, the company has raised $752.5 million from major investors such as 137 Ventures, Andreessen Horowitz, Baillie Gifford, Bedrock Capital, Brookfield Growth Partners, Founders Fund, Franklin Templeton, and Moore Strategic Ventures.

“We founded RigUp in 2014 on the premise that technology could be used to more efficiently and effectively source skilled labor across the oil and gas industry. In the years that ensued, we found that our approach could be taken further; we could help address a much larger socioeconomic shift across the infrastructure industry,” co-founder and CEO Xuan Yong said last year.

“Today, Workrise reflects our aim to bridge the skilled labor gap across industries, to leverage technology and data to empower skilled workers — and, in turn, the economy at large — so the U.S. can prepare for an infrastructure renaissance,” he added.

A little over a year after its rebranding, Workrise laid off an undisclosed number of employees and streamlined its business offerings. Before the layoffs, the company was valued at $2.9 billion.

“Filling the skilled labor gap will be essential to our continued economic growth and recovery, and Workrise is at the forefront of that effort,” Allen Narcisse, chief operating officer at Workrise, said last year. “Workrise has already proven that traditional ways of staffing large projects are ripe for disruption.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.